-1 	|BT| (NP (NP (JJ Chemopreventive) (NN evaluation) (NN Tephrosia) (NN purpurea) (JJ N-nitrosodiethylamine-induced) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))) |ET| |BS|225:E05.337 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890|ES| 19:1 849:1 900:1 2503:1 2603:1 2948:1 3972:1 3994:1 3995:1
-1 	|BT| (S (NP (JJ Chronic) (NN ethanol) (NN feeding)) (VP (VBZ accelerates) (NP (JJ hepatocellular) (NN carcinoma) (NN progression) (JJ sex-dependent) (NN manner)) (NP (NN mouse) (NN model) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 751:D02.033.375 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810|ES| 19:1 48:1 52:1 72:1 303:1 304:1 529:1 900:1 1668:1 2942:1 3440:1 3967:1 4105:1
-1 	|BT| (S (S (NP (JJ Chronic) (JJ inorganic) (JJ arsenic) (NN exposure)) (VP (VBZ induces) (NP (JJ hepatic) (JJ global) (JJ individual) (NN gene) (NN hypomethylation)))) (: :) (NP (NN implication) (JJ arsenic) (NN hepatocarcinogenesis))) |ET| |BS|6:G05.360.340.024.340 197:A01.456.505.420 493:M01 1158:D01.268.513.249|ES| 9:1 19:1 85:1 104:1 214:1 660:1 838:1 900:1 1953:1 2512:1 3174:1 3967:1 4106:1 4107:1
-1 	|BT| (S (NP (NN Colitis)) (VP (VBD induced) (NP (NP (NN knockout)) (, ,) (NP (NP (NP (JJ transgenic) (, ,) (NN control)) (PRN (-LRB- -LRB-) (NP (NN C57BL/B6)) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN administration) (NN dextran) (NN sulfate) (NN sodium)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN mouse)) (VP (VBN given) (NP (NN azoxymethane))))) (VP (VBP induce) (NP (JJ colorectal) (NN carcinogenesis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 131:D09.698.365.272.300 132:D02.172.080 352:B01.050.050.136 593:B01.050.050.199.520.520.420|ES| 2:1 10:1 14:1 17:1 19:1 29:1 52:1 71:1 207:1 243:1 285:1 289:1 406:1 407:1 412:1 1993:1 2575:1 3300:1 3306:1 4108:1 4109:1
-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (NP (DT These) (VBP result) (NP (VBN suggested) (NN TFA) (VBD protected) (ADJP (NN mouse) (JJ CCl4-induced) (ADJP (NN liver) (NN injury) (JJ antioxidant)) (NN stress) (JJ antiinflammatory)) (NN effect)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217|ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN In) (NP (NNS hepatocytes))) (, ,) (NP (NN JNK1) (NN JNK2)) (VP (VP (VBP appear) (NP (NP (JJ combined) (NN effect)) (VP (VBG protecting) (NP (NN mouse) (NN CCl4))))) (: -) (NP (JJ acetaminophen-induced) (NN liver) (NN injury)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 262:A11.436.348 661:D02.065.199.092.040|ES| 2:1 19:1 52:1 75:1 104:1 164:1 239:1 244:1 836:1 894:1 2251:1 2357:1 2416:1 4110:1 4111:1 4112:1 4113:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (S (NP (VBN truncated) (NN PPARalpha) (NN splice) (JJ variant) (NN function)) (NP (NP (JJ endogenous) (NN inhibitor) (JJ proliferative) (JJ pro-inflammatory) (NN gene)) (SBAR (S (NP (JJ human) (NN cell) (NN absence) (NN mouse)) (VP (MD may) (VP (VB explain) (NP (JJ species-specific) (NN difference) (JJ fibrate-induced) (NN hepatocarcinogenesis))))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 55:B01.050.150.900.649.801.400.112.400.400 536:D12.776.826.239.500 1185:D12.125.072.401.623 1186:G16.824|ES| 9:1 19:1 33:1 36:1 52:1 94:1 104:1 239:1 380:1 491:1 658:1 793:1 796:1 900:1 990:1 1534:1 1674:1 3870:1 4114:1 4115:1 4116:1 4117:1 4118:1 4119:1 4120:1 4121:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NN Silibinin) (NN target) (NN beta-catenin) (NN IGF-1Rbeta) (NN pathway) (JJ chemopreventive) (NN efficacy) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937|ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1
-1 	|BT| (S (NP (JJ Concurrent) (NN administration) (JJ ascorbic) (NN acid)) (VP (VBZ enhances) (NP (NP (NN liver) (JJ tumor-promoting) (NN activity)) (JJ kojic) (NN acid) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1187:D02.241.081.844.107|ES| 19:1 399:1 836:1 849:1 1275:1 1356:1 2575:1 3776:1 4122:1 4123:1 4124:1
-1 	|BT| (S (NP (JJ Considerable) (NN attention)) (VP (VBD focused) (NP (NP (JJ peroxisome) (JJ proliferator-induced) (JJ hepatocellular) (NN carcinoma)) (, ,) (SBAR (S (NP (NN phenomenon)) (VP (VBD noted) (NP (NN man)))))) (, ,) (SBAR (IN whereas) (S (NP (JJ limited) (NN study)) (VP (VBP examine) (VP (VBZ fibrates) (SBAR (S (NP (JJ therapeutic) (NN drug)) (VP (VBP induce) (NP (NP (NN cholestasis)) (, ,) (NP (JJ common) (NN finding) (JJ human)))))))))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 104:C04.557.470.200.025.255 275:C23.888 879:C06.130.120.135 905:F02.830.104.214 912:D27.888.569.100.675 1188:D02.241.081.114.968.500 1189:M01.390|ES| 2:1 19:1 36:1 131:1 191:1 243:1 303:1 304:1 372:1 541:1 655:1 927:1 960:1 1887:1 2131:1 2310:1 3198:1 4125:1 4126:1 4127:1 4128:1 4129:1 4130:1 4131:1
-1 	|BT| (S (NP (NNP Cyclooxygenase) (CD 2) (NN Prostaglandin) (NN E2)) (VP (VBN Involved) (NP (JJ N-Nitrosodiethylamine-Initiated) (JJ Early) (NN Rat) (NN Hepatocarcinogenesis)))) |ET| |BS|24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1118:D10.251.355.255.550.250.200|ES| 19:1 148:1 1959:1 3432:1 3909:1 4008:1 4132:1 4133:1 4134:1 4135:1
-1 	|BT| (NP (NP (NN DESIGN) (: :)) (NP (NP (NP (JJ Spontaneous) (JJ experimental) (NN fibrogenesis)) (SBAR (S (NP (ADJP (RB well) (JJ diethylnitrosamine-induced)) (NN hepatocarcinogenesis)) (VP (VBD investigated) (NP (NP (JJ lecithin-retinol) (NN acyltransferase)) (PRN (-LRB- -LRB-) (NP (NN LRAT)) (-RRB- -RRB-))))))) (: -) (NP (JJ deficient) (NN mouse) (NN lack) (JJ retinoid-containing) (NN lipid) (NN droplet) (NNS HSCs)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393|ES| 10:1 14:1 19:1 52:1 104:1 263:1 403:1 690:1 787:1 900:1 2401:1 2732:1 3381:1 3383:1 3937:1 4136:1 4137:1 4138:1 4139:1 4140:1 4141:1 4142:1
-1 	|BT| (S (NP (NP (NN Dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (VP (VBN given) (S (VP (VBP induce) (NP (NP (NP (NN colitis) (NN C57/BL6)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-))) (NN mouse)))) (, ,) (NP (ADVP (RB well)) (NP (NP (NN mouse) (NN disruption) (NN hydroxyprostaglandin) (NN dehydrogenase) (CD 15) (NN gene)) (PRN (-LRB- -LRB-) (NP (JJ 15-PGDH-knockout) (NN mouse)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Yap1) (NN gene)) (PRN (-LRB- -LRB-) (NP (JJ YAP-knockout) (NN mouse)) (-RRB- -RRB-))) (, ,) (NP (JJ double-knockout) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 53:C06.405.205.265 131:D09.698.365.272.300|ES| 2:1 9:1 10:1 14:1 19:1 29:1 52:1 143:1 243:1 289:1 406:1 407:1 787:1 1602:1 3085:1 3306:1 4143:1 4144:1 4145:1 4146:1 4147:1 4148:1 4149:1 4150:1
-1 	|BT| (S (NP (NN Diethylnitrosamine) (NN initiation)) (VP (VBP alter) (NP (ADJP (JJ clofibric) (JJ acid-induced)) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1190:D02.241.081.114.968.500.500|ES| 19:1 637:1 849:1 900:1 2599:1 4151:1 4152:1 4153:1
-1 	|BT| (S (NP (JJ Diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (VP (VBD suppressed) (NP (NP (JJ heterozygous) (JJ NRDC-deficient) (NN mouse)) (VP (VBN compared) (NP (JJ wild-type) (NNS littermates)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 554:D02.654.442.200|ES| 8:1 19:1 50:1 52:1 307:1 786:1 900:1 1355:1 2569:1 4154:1
-1 	|BT| (S (NP (NNS Effects)) (VP (VBD baked) (S (NP (NP (NP (NN PP)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 20) (NN %)) (NN wt/wt)) (-RRB- -RRB-))) (NN colon) (NNS CSCs)) (ADVP (RB also)) (VP (VBN tested) (NP (FW vivo) (NN mouse) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 556:C11.768.175 1126:Z01.639.760.590.715|ES| 5:1 10:1 14:1 19:1 52:1 78:1 113:1 369:1 378:1 1870:1 1966:1 2533:1 2988:1 3461:1 3941:1 3942:1 4155:1
-1 	|BT| (S (NP (VBN Enhanced) (NP (NN liver)) (NN tumor) (NN promotion) (NN activity) (NN rat)) (VP (VBN subjected) (NP (JJ combined) (NN administration) (JJ phenobarbital) (NN orphenadrine)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1159:D02.092.471.600|ES| 7:1 19:1 164:1 399:1 836:1 849:1 2337:1 2575:1 2685:1 3267:1 3466:1 4005:1
-1 	|BT| (S (S (NP (NP (NN Ethanol)) (VBD diminished) (JJ hepatic) (NN function)) (VP (VBD increased) (NP (NN liver) (NN damage)))) (, ,) (S (NP (NP (NN ethanol)) (ADVP (RB alone))) (VP (VBP induce) (NP (JJ hepatic) (NN foci/HCC) (NN formation))))) |ET| |BS|20:G03.495 104:C04.557.470.200.025.255 242:A03.620 751:D02.033.375|ES| 2:1 19:1 33:1 43:1 47:1 241:1 243:1 836:1 838:1 1848:1 3178:1 3440:1 4156:1 4157:1
-1 	|BT| (NP (NP (NP (NN Evaluation) (JJ chemopreventive) (NN effect)) (NP (NNP Fumaria) (NN indica) (NN N-nitrosodiethylamine) (JJ CCl4-induced) (JJ hepatocellular) (NN carcinoma) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750|ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1
-1 	|BT| (NP (NP (NN Evolution) (JJ genomic) (NN instability) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 1191:C23.550.362 1192:G05.355.044|ES| 19:1 52:1 900:1 910:1 1299:1 2732:1 4158:1
-1 	|BT| (NP (NP (NP (NP (NN Expression) (NN analysis) (NN group) (NN IIA) (JJ secretory) (NN phospholipase) (NN A)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (NN mouse) (JJ differential) (NN susceptibility) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 192:D08.811.277.352.100.680.750.937.750 401:C23.550.291.687 829:M01.686|ES| 10:1 14:1 19:1 52:1 69:1 78:1 113:1 148:1 316:1 643:1 644:1 661:1 1353:1 1677:1 2222:1 2300:1 2533:1
-1 	|BT| (S (S (NP (NN Expression) (NN retinoid) (NN X) (NN receptor) (NN alpha)) (VP (VBD decreased) (NP (CD 3) ('' ')))) (: -) (FRAG (NP (JJ methyl-4-dimethylaminoazobenzene-induced) (JJ hepatocellular) (NN carcinoma) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 941:D12.776.826.701.500.500 1193:D02.092.146.325|ES| 19:1 186:1 202:1 303:1 304:1 316:1 849:1 929:1 1836:1 2573:1 4159:1
-1 	|BT| (S (PP (VBG Following) (NP (NP (JJ initial) (CD 14) (NN day)) (JJ dietary) (NN dose) (NN range-finding) (NN study) (JJ male) (NN mouse))) (, ,) (ADJP (NP (NP (JJ mechanistic) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (CD 0) (, ,) (CD 3) (, ,) (CD 32) (, ,) (CD 320) (NN ppm) (NN toxaphene) (NN diet) (CD 7)) (, ,) (NP (CD 14)) (, ,) (NP (ADJP (CD 28) (NN day)) (NN treatment))) (-RRB- -RRB-))) (VBN performed)) (VP (VBP examine) (SBAR (S (NP (JJ potential) (NN mechanism) (NN toxaphene)) (VP (VBD induced) (NP (NN mouse) (NN liver) (NN tumor))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 275:C23.888 515:C04.588.274.623 595:G07.203.650.240 596:E02.642.249 1149:D02.455.526.439.913|ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 162:1 412:1 458:1 546:1 827:1 836:1 862:1 960:1 988:1 1401:1 1402:1 1440:1 1890:1 2191:1 2301:1 2546:1 2594:1 3233:1 3985:1 4078:1 4160:1 4161:1 4162:1 4163:1 4164:1
-1 	|BT| (S (PP (IN For) (NP (FW vivo) (NN study))) (, ,) (NP (JJ 1,2-dimethylhydrazine) (NN dihydrochloride) (-LRB- -LRB-) (NN DMH) (-RRB- -RRB-) (NN s.c.)) (VP (VBD injected) (VP (VBP induce) (NP (NP (NP (NN colon) (NN cancer) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NN PPARgamma) (PRN (-LRB- -LRB-) (CC +) (: /) (: -)))) (-RRB- -RRB-) (NP (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 719:D12.776.826.239.588|ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 131:1 243:1 378:1 2588:1 2642:1 2643:1 3489:1 3586:1 4165:1 4166:1
-1 	|BT| (S (NP (JJ Garlic) (NN oil)) (VP (VBD attenuated) (NP (NP (JJ nitrosodiethylamine-induced) (NN hepatocarcinogenesis)) (VP (VBG modulating) (NP (JJ metabolic) (NN activation) (NN detoxification) (NN enzyme)))))) |ET| |BS|554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811|ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1
-1 	|BT| (NP (NP (NP (NN Glutathione) (NN S-transferase) (JJ placental) (-LRB- -LRB-) (NN GST-P) (-RRB- -RRB-)) (: -) (NP (NP (JJ negative) (JJ hepatocellular) (JJ altered) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN HAF)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (NN HCA)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBD generated) (NP (NP (NP (NP (CD two) (JJ initiation-promotion) (NN model) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN NDEN)) (-RRB- -RRB-))) (NP (NN peroxisome) (NNS proliferators))) (, ,) (NP (NN Wy-14,643) (NN clofibrate)))))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 780:D08.811.913.225.500 783:A16.710 910:D02.241.081.114.968.500.500.195 912:D27.888.569.100.675 1194:C04.557.470.035.120|ES| 2:1 10:1 14:1 19:1 42:1 72:1 73:1 303:1 304:1 441:1 693:1 933:1 1431:1 1887:1 2446:1 2602:1 2743:1 2745:1 3058:1 3200:1 4167:1 4168:1 4169:1 4170:1 4171:1 4172:1 4173:1
-1 	|BT| (NP (NP (NP (NN GP73)) (PRN (-LRB- -LRB-) (PRN (: -) (: /) (: -)) (-RRB- -RRB-))) (, ,) (NP (NN GP73) (PRN (-LRB- -LRB-) (CC +) (: /) (: -)) (-RRB- -RRB-) (, ,) (NP (NP (NN GP73) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-)) (NN mouse)) (VP (VBN given) (NP (NN injection) (NN diethylnitrosamine))))) (S (VP (VBP induce) (NP (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 242:A03.620 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 29:1 44:1 45:1 51:1 52:1 243:1 785:1 836:1 1952:1 2416:1 4174:1
-1 	|BT| (S (NP (NN GT-094) (JJ first) (NN nitrate)) (VP (VBD reported) (VP (VB reduce) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 45) (NN %)) (-RRB- -RRB-))) (NP (VBN administered) (NN carcinogen) (NN standard) (NN azoxymethane) (NN rat) (NN model) (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 824:C04.834.020 1195:D01.248.497.158.606|ES| 10:1 14:1 17:1 18:1 19:1 72:1 369:1 816:1 849:1 993:1 1431:1 1725:1 1993:1 2125:1 2336:1 2361:1 2913:1 4175:1 4176:1 4177:1 4178:1
-1 	|BT| (S (ADVP (RB Hence)) (, ,) (NP (NN chloroform)) (VP (VBD prevented) (SBAR (S (NP (NN hypomethylation)) (VP (VBD increased) (NP (NP (NN mRNA)) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN tumor) (NN DCA)) (, ,) (S (VP (VBG enhancing) (NP (JJ DCA-promotion) (NN kidney) (NN tumor))))))))) |ET| |BS|111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224|ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1
-1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NN diethylnitrosamine) (JJ hepatic) (NN deletion) (NN PTEN)))) |ET| |BS|306:G05.355.600.800 554:D02.654.442.200|ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1
-1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (ADJP (JJ diethylnitrosamine/phenobarbital) (PRN (-LRB- -LRB-) (NP (NN DEN/PB)) (-RRB- -RRB-))))) |ET| |BS|554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 10:1 14:1 19:1 412:1 1959:1 4182:1 4183:1
-1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (JJ male) (NP (NP (JJ Sprague-Dawley) (NN rat) (JJ chronic) (NN feeding) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN 2-AAF)) (-RRB- -RRB-))) (NN dose) (ADJP (CD 0.05) (NN %)) (JJ basal) (NN diet)) (NP (JJ daily) (CD 5) (NN day) (NN week))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 595:G07.203.650.240 596:E02.642.249 767:D02.065.064.150 769:B01.050.150.900.649.865.635.505.700.750 881:D02.065.064.150|ES| 10:1 14:1 19:1 369:1 412:1 578:1 783:1 849:1 1402:1 1790:1 1959:1 2191:1 2301:1 2696:1 2707:1 2942:1 3271:1 3849:1 4078:1 4184:1 4185:1
-1 	|BT| (NP (NP (JJ Hepatocarcinogenic) (NN susceptibility) (NN fenofibrate) (JJ possible) (NN mechanism) (NN carcinogenicity) (JJ two-stage) (NN hepatocarcinogenesis) (NN model) (NN rasH2) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 401:C23.550.291.687 916:D02.241.081.114.968.500.625|ES| 19:1 52:1 72:1 162:1 900:1 1353:1 1359:1 2971:1 3225:1 3583:1 4186:1 4187:1
-1 	|BT| (S (NP (JJ Hepatocellular) (NN carcinoma)) (VP (VBD found) (NP (CD four) (CD five) (NN rat) (CD 12) (NN month) (NN tamoxifen) (NN treatment)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900|ES| 19:1 37:1 304:1 546:1 770:1 849:1 1120:1 2151:1 2371:1 2723:1 4188:1
-1 	|BT| (S (NP (NN Hepatocyte) (JJ nuclear) (NN factor) (CD 4) (NN alpha) (NN deletion)) (VP (VBZ promotes) (S (NP (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)) (ADJP (JJ rodent))))) |ET| |BS|104:C04.557.470.200.025.255 306:G05.355.600.800 514:B01.050.150.900.649.865 554:D02.654.442.200 1197:D12.776.260.262.968|ES| 19:1 185:1 298:1 303:1 304:1 319:1 1059:1 1256:1 1836:1 2173:1 2349:1 2732:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBN conducted) (S (NP (NP (NP (CD two) (NN stage) (NN hepatocarcinogenesis) (NN study) (NN rat)) (VP (VBN exposed) (S (VP (VBG initiating) (NP (NP (NN agent) (NN nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))))) (, ,) (NP (NP (JJ hepatotoxic) (NN compound) (NN thioacetamide)) (PRN (-LRB- -LRB-) (NP (NN TAA)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN methapyrilene)) (PRN (-LRB- -LRB-) (NP (NN MP)) (-RRB- -RRB-))) (VP (NN acetaminophen) (S (-LRB- -LRB-) (NP (NN APAP) (-RRB- -RRB-) (CD 1-2) (NP (NN week))) (VP (VBD followed) (NP (NP (NN liver) (NN tumor) (NN promoter) (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))))))))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 296:D02.065.064.786 554:D02.654.442.200 600:D27.888.569.100 661:D02.065.199.092.040 756:D03.383.742.698.253.650 876:F01.145 1198:D02.092.782.258.368.500|ES| 2:1 7:1 10:1 14:1 19:1 83:1 131:1 400:1 728:1 783:1 836:1 849:1 900:1 933:1 1035:1 1129:1 1875:1 2019:1 2412:1 2433:1 2685:1 2862:1 3100:1 3102:1 3130:1 3496:1 4189:1 4190:1 4191:1 4192:1 4193:1 4194:1
-1 	|BT| (SINV (ADVP (RB Here)) (, ,) (VP (VBN examined) (NP (NP (NP (JJ chemopreventive) (JJ potential) (NN Acteoside)) (PRN (-LRB- -LRB-) (NP (NN ACT)) (-RRB- -RRB-))) (, ,) (NP (NP (NN plant)) (VP (VBN derived) (NP (NP (JJ phenylethanoid) (NN glycoside) (JJ environmental) (JJ dietary) (NN carcinogen)) (, ,) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (S (: -) (VP (VBN induced) (NP (NN rat) (NN hepatocarcinogenesis)))))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 328:B01.650 554:D02.654.442.200 595:G07.203.650.240 1199:D04.808.155.580 1200:G16.500.275 1201:D09.408|ES| 2:1 10:1 14:1 19:1 324:1 400:1 409:1 827:1 849:1 900:1 1098:1 1721:1 1875:1 1946:1 1952:1 2125:1 2594:1 3446:1 4195:1 4196:1 4197:1 4198:1
-1 	|BT| (S (S (ADVP (RB Here)) (, ,) (VP (VBD identified) (SBAR (S (NP (JJ novel) (NN mechanism) (NN alcohol)) (VP (VBZ accelerates) (NP (NN liver) (NN fibrosis))))))) (: :) (NP (NP (NN inhibition) (JJ antifibrotic) (NN effect)) (SBAR (S (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (VP (NN cell) (NP (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-)))))))) |ET| |BS|43:F01.145.544 259:D12.776.395.240.150.500 676:C06.552.630 751:D02.033.375 822:D02.033 1033:D12.644.276.374.440.893 1202:A11.118.637.555.567.537|ES| 2:1 10:1 14:1 19:1 75:1 94:1 103:1 104:1 162:1 400:1 529:1 623:1 836:1 891:1 949:1 2333:1 2885:1 3710:1 4199:1 4200:1 4201:1 4202:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NN level) (NN MT-1) (NN MT-2A)) (ADVP (RB drastically)) (VP (VBD reduced) (NP (JJ primary) (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NNS HCCs)) (-RRB- -RRB-))) (JJ diethylnitrosamine-induced) (NN liver) (NN tumor) (NN mouse)) (, ,) (NP (ADVP (RB primarily)) (JJ due) (NP (JJ transcriptional) (NN repression))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 208:F01.393.821 209:G02.111.087.847 515:C04.588.274.623 554:D02.654.442.200|ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 249:1 303:1 304:1 344:1 400:1 417:1 452:1 559:1 706:1 836:1 1132:1 1970:1 2732:1 2851:1 4203:1 4204:1 4205:1
-1 	|BT| (S (ADVP (RB Herein)) (NP (ADJP (NN report) (JJ concurrent)) (NP (NN increase) (NN liver) (NN progenitor) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNS LPCs)) (-RRB- -RRB-))) (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (VP (NN diethylnitrosamine) (S (-LRB- -LRB-) (NP (NN DEN) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN rat) (NN hepatocarcinogenesis) (JJ cirrhotic) (NN liver) (NN HCC) (NN patient)))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 503:D12.644.276.374.687 554:D02.654.442.200|ES| 10:1 14:1 19:1 40:1 94:1 102:1 120:1 409:1 417:1 428:1 441:1 836:1 849:1 900:1 1772:1 1773:1 1774:1 1875:1 1952:1 2968:1 4206:1 4207:1 4208:1
-1 	|BT| (S (ADVP (RB Herein)) (VP (VBP show) (SBAR (S (NP (JJ global) (NN loss) (NN ERRalpha)) (VP (VBZ accelerates) (NP (NP (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (: -) (S (VP (VBN induced) (NP (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|104:C04.557.470.200.025.255 197:A01.456.505.420 554:D02.654.442.200|ES| 10:1 14:1 19:1 32:1 35:1 303:1 304:1 409:1 428:1 429:1 529:1 660:1 1875:1 1952:1 4209:1
-1 	|BT| (S (NP (ADVP (RB Herein)) (, ,) (JJ first) (NN time)) (, ,) (VP (VBP investigate) (NP (FW vivo) (NN efficacy) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910|ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1
-1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (NP (NN MMP10) (NN expression) (NN function)) (JJ human) (JJ hepatocellular) (NN carcinoma) (-LRB- -LRB-) (NN HCC) (-RRB- -RRB-) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 33:1 36:1 52:1 115:1 303:1 304:1 403:1 409:1 428:1 441:1 900:1 1875:1 1952:1 4210:1
-1 	|BT| (NP (NP (JJ High-saturate-fat) (NN diet) (NN delay) (NN initiation) (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 694:G07.203.650.240.267|ES| 19:1 136:1 303:1 304:1 637:1 2191:1 2732:1 4211:1
-1 	|BT| (NP (NP (ADVP (RB However)) (PRN (, ,) (NP (JJ Ptk6-null) (NN mouse)) (ADVP (RB also)) (NP (JJ resistant) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis))))) |ET| |BS|29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 2:1 5:1 19:1 52:1 78:1 113:1 427:1 433:1 2533:1 4212:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NNP Sorafenib) (NN treatment)) (ADVP (RB transiently)) (VP (VBD inhibited) (SBAR (S (NP (NN cell) (NN cycle) (NN progression)) (VP (VBD resulted) (SBAR (S (NP (JJ mitotic) (NN catastrophe)) (VP (VBD enhanced) (NP (JJ non-apoptotic) (NN liver) (NN injury) (NN regeneration)))))))))) |ET| |BS|16:C23.550.291.656 39:G04.299.139.160 52:E02 122:C14.280.383 353:G04.299.134 925:G10.261.326.520|ES| 2:1 19:1 48:1 94:1 365:1 385:1 433:1 546:1 594:1 601:1 720:1 836:1 2416:1 2833:1 3210:1 3260:1 3614:1 4213:1
-1 	|BT| (FRAG (ADVP (RB However)) (, ,) (NP (NP (NN action) (NN compound) (JJ ethanol-induced) (NN liver) (NN injury)) (ADJP (RB still) (JJ unknown)))) |ET| |BS|242:A03.620 751:D02.033.375|ES| 2:1 19:1 433:1 776:1 836:1 2013:1 2182:1 2416:1 2433:1 2674:1
-1 	|BT| (S (NP (NN HTHQ)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN carcinogenesis) (CD two) (NN stage) (NN colon) (NN carcinogenesis) (NN model)) (S (VP (VBG using) (NP (NP (NP (NN 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-))) (NN initiator))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725|ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1
-1 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN GEN-27)) (VP (VBD protected) (FRAG (NP (NP (NN mouse) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (: /) (FRAG (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (: -) (NP (NP (VBN induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (VBD reduced) (NN mortality)) (, ,) (NP (NN tumor) (NN number) (NN tumor) (NN volume))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 695:E05.318.308.985.550 1203:E05.041.124.892|ES| 2:1 7:1 10:1 14:1 19:1 52:1 113:1 207:1 406:1 407:1 409:1 452:1 646:1 1993:1 1994:1 2413:1 2511:1 2651:1 3305:1 3306:1 3589:1 4214:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN mouse) (NNP Diethylnitrosamine) (NN model) (NN hepatocarcinogenesis)) (VP (VBN observed) (NP (JJ strong) (NN induction) (NN CXCR7) (NN CXCL11) (NN transcript)) (, ,) (S (VP (VBG confirming) (NP (NN CXCR7/CXCL11) (NN up-regulation) (VBN conserved) (JJ human) (NN mouse) (NN liver) (NN cancer)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 554:D02.654.442.200|ES| 2:1 18:1 19:1 36:1 52:1 72:1 244:1 261:1 468:1 736:1 836:1 896:1 900:1 937:1 3578:1 4151:1 4215:1 4216:1 4217:1 4218:1 4219:1
-1 	|BT| (S (PP (IN In) (NP (NP (JJ experimental) (NN mouse) (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (JJ diethylnitrosamine-induced)) (-RRB- -RRB-)))) (, ,) (NP (NN tumor)) (VP (VBD showed) (NP (NP (VBN increased) (NN activation) (NN TGF-beta) (NN pathway)) (VBD enhanced) (NN CXCR4) (NN level)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 95:E05.599 503:D12.644.276.374.687 554:D02.654.442.200 1204:D12.776.543.750.100.160.500.400|ES| 2:1 7:1 10:1 14:1 19:1 47:1 52:1 72:1 132:1 225:1 244:1 249:1 263:1 383:1 385:1 900:1 1774:1 2732:1 4220:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (NN dioscin) (NN show) (JJ excellent) (JJ protective) (NN effect)) (JJ ethanol-induced) (NN liver) (NN injury)) (S (VP (VBG ameliorating) (NP (NP (JJ ethanol-induced) (JJ oxidative) (NN stress)) (, ,) (NP (JJ mitochondrial) (NN function)) (, ,)) (NP (NP (JJ inflammatory) (NP (NN cytokine)) (NN production)) (, ,) (NP (NN apoptosis) (NN liver) (NN steatosis)) (, ,))))) (VP (VBD developed) (NP (JJ new) (NN drug) (NN treatment) (JJ ethanol-induced) (NN liver) (NN injury) (NN future)))) |ET| |BS|39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241|ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (CD three) (CD 18) (NN vinyl) (JJ carbamate-induced) (NN liver) (NN tumor)) (, ,) (NP (CD one) (CD 18) (JJ TCDD-induced) (NN liver) (NN tumor)) (, ,) (NP (CD two) (CD 22) (JJ spontaneous) (NN liver) (NN neoplasm) (NN mutation) (NN beta-catenin)))) |ET| |BS|18:G05.365.590 23:D12.776.091.249 491:D27.505.259.500 515:C04.588.274.623 1096:D03.383.231.900|ES| 2:1 7:1 19:1 34:1 60:1 244:1 283:1 482:1 836:1 933:1 1010:1 1193:1 1392:1 1523:1 3714:1 4221:1 4222:1 4223:1
-1 	|BT| (S (PP (IN In) (NP (JJ medium-term) (NN carcinogenesis) (NN test) (NN rat))) (, ,) (NP (NP (ADJP (CD 2.0) (NN %)) (NN KA)) (VP (ADVP (RB orally)) (VBN given) (NP (NN F344/DuCrj) (NN rat) (CD 4) (NN week) (NN initiation) (NN period))) (, ,)) (VP (VBD followed) (NP (NP (NN combination) (JJ partial) (NN hepatectomy) (NN treatment) (NN hepatocarcinogenesis) (NN promoter)) (, ,) (NP (NP (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-)))))) |ET| |BS|52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200 756:D03.383.742.698.253.650 776:G01.910.645 849:G08.686.785.760.769.490.500 914:L01.178 928:E04.210.556 1205:E05.940.150|ES| 2:1 10:1 14:1 19:1 29:1 83:1 207:1 244:1 319:1 369:1 530:1 546:1 637:1 783:1 849:1 900:1 1418:1 2685:1 2725:1 3130:1 3215:1 3272:1 3273:1 3496:1 4224:1 4225:1 4226:1 4227:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN mouse) (NN fed) (NN bezafibrate) (CD 1) (NN year))) (, ,) (NP (NP (JJ preneoplastic) (NN focus)) (, ,) (NP (NP (NP (NN adenoma) (JJ hepatocellular) (NN carcinoma)) (VP (VBN found))) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NN mouse)) (, ,) (NP (NP (JJ single) (JJ microscopic) (NN adenoma)) (VP (VBD found) (S (NP (NP (CD one)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 104:C04.557.470.200.025.255 426:E01.370.350.515 663:C16.320.565.398.500.330.500 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 909:D02.065.277.067|ES| 2:1 10:1 14:1 19:1 37:1 42:1 45:1 51:1 52:1 98:1 244:1 303:1 304:1 1010:1 1431:1 1438:1 1452:1 2426:1 2846:1 3201:1 4071:1
-1 	|BT| (SINV (PP (IN In) (NP (NN order))) (VP (VBP prepare)) (NP (NP (JJ human) (NN trial) (NN inhibition) (NN colon) (NN carcinogenesis)) (, ,) (NP (NP (VBN conducted) (NN study) (JJ green) (NN tea) (NNS polyphenols)) (VP (JJ preventive) (VP (NN agent) (NP (NN azoxymethane) (S (-LRB- -LRB-) (NP (NN AOM) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN rat) (NN colon) (NN cancer) (NN model)) (S (VP (VBG using) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN end) (NN point)))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 43:F01.145.544 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 375:Z01.639.100 824:C04.834.020 841:E05.318.760.250.500 876:F01.145|ES| 2:1 10:1 14:1 18:1 19:1 36:1 72:1 103:1 113:1 131:1 154:1 207:1 244:1 350:1 409:1 728:1 849:1 1431:1 1725:1 1883:1 1993:1 1994:1 2121:1 2379:1 2834:1 2913:1 2914:1 2989:1 3100:1 3192:1 4228:1 4229:1
-1 	|BT| (FRAG (PP (IN In) (NP (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN model) (NN colon) (NN cancer))) (, ,) (NP (NP (NN addition) (NN K-ras) (NN mutation)) (, ,) (VP (VBN shown) (S (NP (ADJP (ADJP (JJ wild-type)) (PRN (-LRB- -LRB-) (ADJP (JJ WT)) (-RRB- -RRB-))) (NN Ras)) (VP (VBD activated) (NP (NP (JJ upstream) (NN pathway)) (, ,) (S (VBG including) (, ,) (PP (FW e.g.)) (, ,) (VP (VBG signaling) (NP (NN ErbB) (NN receptor)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009|ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1
-1 	|BT| (S (PP (IN In) (NP (JJ azoxymethane-treated) (NN rat) (NN model) (JJ experimental) (NN colon) (NN carcinogenesis))) (, ,) (NP (NN sulindac) (NN treatment)) (ADVP (RB markedly)) (VP (VBD induced) (NP (NP (NNP Csk) (JJ corresponding) (NN increase) (JJ inhibitory) (NN phosphorylation) (NN Src)) (PRN (-LRB- -LRB-) (NP (NN Tyr) (PRN (-LRB- -LRB-) (CD 527) (-RRB- -RRB-)) (-RRB- -RRB-)))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 52:E02 95:E05.599 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 634:D12.125.072.050.875 972:G02.111.087.677 1206:D08.811.682.690.708.125.500|ES| 2:1 10:1 14:1 19:1 40:1 72:1 113:1 207:1 244:1 263:1 412:1 546:1 849:1 869:1 2396:1 2429:1 2793:1 3426:1 3674:1 4230:1 4231:1 4232:1 4233:1
-1 	|BT| (FRAG (PP (IN In) (ADJP (JJ present) (SBAR (S (NP (NP (NN paper)) (, ,) (NP (NP (JJ ethanol-induced) (JJ acute) (JJ chronic) (NN liver) (NN damage) (NN rat) (NN model)) (VP (VBN used))) (, ,)) (VP (VBP result) (VP (VBD showed) (SBAR (S (NP (NN dioscin)) (ADVP (RB significantly)) (VP (VBD alleviated) (SBAR (S (NP (NP (NN liver) (NN steatosis)) (, ,) (NP (VBN reduced) (NN level) (NN alanine) (NN aminotransferase)) (, ,) (NP (NN aspartate) (NN aminotransferase)) (, ,) (NP (NP (JJ total) (NN triglyceride)) (PRN (-LRB- -LRB-) (NP (NN TG)) (-RRB- -RRB-))) (, ,) (NP (JJ total) (NN cholesterol) (NN malondialdehyde)) (, ,)) (VP (VBD increased) (NP (NP (NN level) (JJ high-density) (NN lipoprotein)) (, ,) (NP (NN superoxide) (NN dismutase)) (, ,) (NP (NN glutathione) (NN glutathione) (NN peroxidase)))))))))))))))) |ET| |BS|58:D08.811.682.881 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 655:D04.808.247.222.284 751:D02.033.375 753:C06.552.241 991:D08.811.682.732.500 1207:D08.811.913.477.700.225 1208:D12.644.456.448 1209:D10.532.432 1210:D02.047.700 1211:J01.637.650 1212:D10.351.801|ES| 2:1 10:1 14:1 19:1 47:1 72:1 90:1 101:1 124:1 132:1 146:1 147:1 244:1 249:1 452:1 476:1 836:1 849:1 1307:1 1790:1 1848:1 2392:1 2393:1 2403:1 2672:1 2674:1 2678:1 2744:1 3132:1 3485:1 4234:1 4235:1 4236:1 4237:1 4238:1 4239:1 4240:1 4241:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN shown) (NP (NP (JJ myrtenal) (, ,) (JJ natural) (NN monoterpene)) (, ,) (NP (VP (VBP act) (SBAR (S (NP (JJ antineoplastic) (NN agent) (NN diethylnitrosamine)) (VP (VBD induced) (NP (JJ phenobarbital) (VBN promoted) (NP (JJ experimental) (JJ hepatocellular) (NN carcinoma))))))))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575|ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (S (VP (VBG using) (NP (FW vivo) (NN model) (NN rat) (NN hepatocarcinogenesis)))) (VP (VP (VBD induced) (NP (NN 2-acetylaminofluorene))) (, ,) (VP (VBD found) (NP (JJ extensive) (NN alteration) (JJ cellular) (NN iron) (NN metabolism) (JJ preneoplastic) (NN stage) (NN liver) (NN carcinogenesis))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 41:A11 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 881:D02.065.064.150 895:D01.490.600 896:D01.268.556.412 898:G03.495|ES| 2:1 19:1 37:1 72:1 131:1 207:1 244:1 350:1 378:1 412:1 836:1 849:1 900:1 951:1 1129:1 1307:1 1438:1 3074:1 3162:1 3163:1 3271:1 4242:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBP demonstrate) (NP (NP (JJ altered) (NN gene) (NN expression) (JJ various) (NNS proteins/enzymes)) (VP (VBN involved) (NP (NP (NN DNA) (NN repair)) (, ,) (NP (NP (NN cell) (NN growth) (NN cell) (NN cycle) (NN process)) (JJ tamoxifen-induced) (NN hepatocarcinogenesis))))))) |ET| |BS|41:A11 45:G07.700.320.249 353:G04.299.134 640:D02.455.426.559.389.150.700.900 730:D08.811 1134:G02.111.087.219 1213:D12.776|ES| 2:1 9:1 19:1 94:1 102:1 115:1 131:1 244:1 502:1 513:1 601:1 638:1 666:1 693:1 774:1 900:1 1096:1 1307:1 3965:1 3966:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN shown) (NN diosmin)) (VP (VBZ attenuates) (SBAR (S (NP (NP (NN 2-AAF)) (VP (VBD induced) (NP (NP (NP (JJ hepatic) (NN toxicity) (JJ early) (NN tumor) (NN promotion) (NN marker)) (PRN (-LRB- -LRB-) (NP (NP (NN ODC)) (, ,) (NP (NN PCNA) (NN Ki67))) (-RRB- -RRB-))) (, ,) (NP (JJ chemopreventive) (NN efficacy) (NN DEN))))) (VP (VBD initiated) (NP (JJ 2-AAF) (VBN promoted) (NN hyper-proliferation) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))))) |ET| |BS|376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740|ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN investigated) (S (NP (NP (NN role) (NN IDO) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NP (NP (NN IDO-knockout)) (PRN (-LRB- -LRB-) (NP (NN KO)) (-RRB- -RRB-))) (NN mouse)))))))) |ET| |BS|15:F01.829.316.616 29:B01.050.050.136.500.500 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 31:1 52:1 131:1 244:1 350:1 403:1 409:1 900:1 1307:1 1875:1 1952:1 2849:1 4243:1 4244:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD investigated) (SBAR (S (NP (NP (NP (JJ chemopreventive) (NN efficacy) (NN PEITC) (NN DBM) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (PRN (: -) (VP (VBN initiated) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (: -))) (VP (VBD promoted) (SBAR (S (NP (NN colon) (NN cancer) (NN mouse) (NN model)) (VP (VBP compare) (NP (NP (JJ potential) (FW vivo) (NN mechanism)) (VP (VBG leading) (NP (NN chemoprevention)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 86:D01.268.556.435 131:D09.698.365.272.300 132:D02.172.080 253:E02.319.162|ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 113:1 131:1 162:1 244:1 378:1 403:1 406:1 407:1 639:1 827:1 870:1 1946:1 1993:1 1994:1 2304:1 3300:1 3306:1 4024:1 4029:1 4245:1 4246:1 4247:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (NP (VBN characterized) (NN cell) (NN signaling) (NN event)) (VP (VBD evoked) (NP (NN decorin) (NN deficiency) (CD two) (JJ experimental) (NN model) (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NN thioacetamide) (NN diethyl) (NN nitrosamine) (NN carcinogen)))))) |ET| |BS|69:G02.111.087.800 87:C18.654.521 95:E05.599 279:D27.888.569.100 296:D02.065.064.786 554:D02.654.442.200 708:D12.776.395.650.750.625|ES| 2:1 19:1 72:1 94:1 131:1 195:1 205:1 244:1 253:1 263:1 350:1 900:1 933:1 985:1 1514:1 2125:1 2901:1 4190:1 4248:1 4249:1
-1 	|BT| (SINV (PP (IN In) (NP (NN study))) (, ,) (VBD evaluated) (FRAG (NP (NN susceptibility) (NNP Vparp)) (: -) (: /) (: -) (NP (NN Tep1) (: -) (: /) (: -) (NN mouse) (JJ dimethylhydrazine-induced) (NN colon) (NN tumorigenesis) (JJ urethane-induced) (NN lung) (NN tumorigenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 182:A04.411 225:E05.337 401:C23.550.291.687 1214:D02.241.081.251.944|ES| 2:1 19:1 52:1 78:1 113:1 131:1 244:1 328:1 780:1 1353:1 4250:1 4251:1 4252:1 4253:1
-1 	|BT| (S (PP (IN In) (NP (JJ wild-type) (NN mouse))) (, ,) (NP (CD 200) (NN ppm) (NN cyproconazole)) (VP (VBD caused) (NP (NP (NP (NP (NN liver) (NN hypertrophy)) (, ,) (NP (VBD increased) (NN liver) (NN weight) (NN cell) (NN proliferation)) (, ,)) (JJ single-cell) (NN necrosis) (JJ fat) (NN vacuolation)) (, ,) (NP (NP (NP (NN effect)) (ADJP (RB generally) (JJ similar))) (VP (VBN caused) (NP (CD 850) (NN ppm) (NN phenobarbital))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 183:G04.299.233.750 242:A03.620 756:D03.383.742.698.253.650 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1151:C06.552.416 1215:C23.888.144.243.926 1216:C23.550.717|ES| 2:1 8:1 19:1 47:1 52:1 75:1 94:1 244:1 299:1 332:1 836:1 2399:1 2425:1 2506:1 2685:1 3233:1 3364:1 3992:1 4254:1 4255:1 4256:1 4257:1 4258:1 4259:1
-1 	|BT| (NP (NP (NN indica)) (NP (NP (-RRB- -RRB-) (NN extract) (-LRB- -LRB-) (NN FIE) (-RRB- -RRB-) (NN N-nitrosodiethylamine) (NN CCl)) (FRAG (-LRB- -LRB-) (NP (NP (CD 4) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))) |ET| |BS|554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1217:A02.513.514.100|ES| 10:1 14:1 19:1 319:1 409:1 849:1 900:1 2496:1 2601:1 2602:1 2603:1 4260:1 4261:1
-1 	|BT| (S (NP (NN Inhibition) (JJ retinoic) (NN acid) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NN N-nitrosomorpholine) (NN expression) (NN myc) (NN oncogene) (NN protein) (JJ Sprague-Dawley) (NN rat)))) |ET| |BS|43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500|ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1
-1 	|BT| (S (NP (NP (NN Inhibition) (JJ azoxymethane-induced) (JJ colorectal) (NN cancer) (NN CP-31398)) (, ,) (NP (NN TP53) (NN modulator)) (, ,) (ADVP (RB alone)) (NP (NN combination) (JJ low) (NNS dos))) (VP (VBP celecoxib) (NP (JJ male) (NN F344) (NN rat)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 132:D02.172.080 590:B01.050.050.199.520.760.200 684:D02.065.884.247|ES| 2:1 17:1 18:1 19:1 241:1 530:1 531:1 849:1 1018:1 1402:1 1607:1 2533:1 2653:1 2703:1 2807:1 3047:1 3185:1
-1 	|BT| (NP (NP (JJ Inhibitory) (NN effect) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1
-1 	|BT| (S (NP (NP (VBN injected) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP induce) (NP (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 554:D02.654.442.200|ES| 10:1 14:1 19:1 243:1 303:1 304:1 1875:1 1952:1 3586:1
-1 	|BT| (S (NP (NP (NN Injection) (NN carcinogen)) (, ,) (NP (NN diethylnitrosamine)) (, ,)) (VP (VBD induced) (SBAR (S (NP (ADJP (RB significantly) (JJR larger)) (NN liver) (NN tumor) (NN HCV) (JJ transgenic) (NN mouse)) (VP (VBP overexpress) (NP (NP (NN PP2Ac)) (VBN compared) (NN control) (NN mouse))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 99:B01.050.050.136.500 226:E02.319.267.530 279:D27.888.569.100 550:B04.450.410 554:D02.654.442.200 1151:C06.552.416|ES| 2:1 7:1 19:1 50:1 52:1 124:1 285:1 289:1 412:1 836:1 1938:1 1952:1 2125:1 2513:1 4079:1 4262:1 4263:1
-1 	|BT| (NP (NP (NP (NN Involvement) (NN Mouse) (JJ Constitutive) (NN Androstane) (NN Receptor) (JJ Acifluorfen-Induced) (NN Liver)) (NP (NNP Injury) (JJ Subsequent) (NN Tumor) (NN Development)))) |ET| |BS|8:C04 242:A03.620|ES| 19:1 1218:1 2059:1 2127:1 2721:1 3399:1 4264:1 4265:1 4266:1 4267:1 4268:1 4269:1
-1 	|BT| (S (NP (PRP It)) (VP (VBD suggested) (SBAR (S (NP (NN CYP2E1)) (ADVP (RB completely)) (VP (VBZ participates) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (, ,) (SBAR (S (NP (JJ high) (NP (NN frequency)) (NN tumor) (JJ wild-type) (NN mouse)) (VP (MD could) (VP (VBN associated) (NP (VBN increased) (NN apoptosis))))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 554:D02.654.442.200 1218:D08.244.453.300|ES| 2:1 7:1 8:1 19:1 47:1 52:1 89:1 169:1 178:1 900:1 908:1 925:1 1247:1 1327:1 2732:1 4270:1 4271:1 4272:1
-1 	|BT| (S (NP (PRP It)) (ADVP (RB also)) (VP (VBD nominated) (NP (NP (JJ dichloroacetic) (NN acid)) (VP (VBN studied) (NP (NP (JJ representative) (NN class) (JJ haloacetic) (NN acid)) (NP (VBN shown) (NN cause) (NN liver) (NN tumor) (NN rat) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1062:D01.029 1219:D02.241.081.018.214.500|ES| 5:1 7:1 19:1 52:1 237:1 401:1 836:1 849:1 1017:1 1275:1 1327:1 1779:1 2814:1 4273:1 4274:1 4275:1
-1 	|BT| (NP (NP (NN JNK) (NN protein)) (VP (VBN activated) (PP (IN via) (NP (NN phosphorylation) (NN response) (NN acetaminophen)))) (FRAG (: -) (NP (NP (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))) (: -) (NP (NP (VBN induced) (NN liver) (NN damage)) (: ;) (S (NP (NN level) (NN activation)) (VP (VBP correlate) (NP (NN degree) (NN injury))))))) |ET| |BS|7:D12.776 242:A03.620 661:D02.065.199.092.040 972:G02.111.087.677 1220:D02.455.526.439.150|ES| 4:1 10:1 14:1 19:1 163:1 217:1 225:1 249:1 409:1 494:1 596:1 836:1 1848:1 2416:1 2806:1 3426:1 4276:1 4277:1 4278:1 4279:1 4280:1 4281:1
-1 	|BT| (S (NP (NN Liver) (NN fibrosis)) (VP (VBD induced) (NP (NP (NN carbon) (NN tetrachloride)) (, ,) (NP (NN bile) (NN duct) (NN ligation)) (, ,) (NP (NP (NN disruption) (JJ multidrug-resistance) (NN transporter) (CD 2) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN Mdr2)) (-RRB- -RRB-)))))) |ET| |BS|227:D12.776.157.530 676:C06.552.630 1220:D02.455.526.439.150 1221:G05.360.340.024.340.361 1222:A03.159.183 1223:E04.426|ES| 2:1 9:1 10:1 14:1 19:1 148:1 412:1 779:1 949:1 1602:1 1621:1 1622:1 2721:1 4278:1 4279:1 4282:1 4283:1 4284:1
-1 	|BT| (S (NP (NN Liver) (NN tumor) (NN formation) (JJ female) (NN rat)) (VP (VBD induced) (NP (NN fluopyram) (JJ mediated) (NN CAR/PXR) (JJ nuclear) (NN receptor) (NN activation)))) |ET| |BS|20:G03.495 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 642:M01.975|ES| 7:1 19:1 43:1 186:1 225:1 412:1 437:1 849:1 1256:1 1404:1 2721:1 4285:1 4286:1
-1 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN etofenprox) (NN rat) (JJ possible) (NN mechanism) (NN action)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 742:G03.787|ES| 7:1 19:1 75:1 162:1 849:1 881:1 1359:1 2013:1 2721:1 4287:1
-1 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBG promoting) (NP (NP (NN effect) (NN orphenadrine) (NN rat) (JJ possible) (NN mechanism) (NN action)) (PP (VBG including) (NP (NN CAR) (NN activation) (JJ oxidative) (NN stress)))))) |ET| |BS|139:J01.937.500.100 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 716:G03.495.710 742:G03.787 1159:D02.092.471.600|ES| 7:1 19:1 75:1 162:1 225:1 421:1 561:1 849:1 881:1 1359:1 2013:1 2522:1 2583:1 2721:1 4005:1
-1 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ male) (NNP Fischer) (NN F344) (NN rat) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))) |ET| |BS|515:C04.588.274.623 554:D02.654.442.200 590:B01.050.050.199.520.760.200|ES| 7:1 10:1 14:1 19:1 412:1 849:1 1402:1 1875:1 1952:1 2721:1 3185:1 4288:1
-1 	|BT| (S (NP (NN Loss) (NN hepatocyte) (NN growth) (NN factor/c-Met) (NN signaling) (NN pathway)) (VP (VBZ accelerates) (SBAR (S (NP (JJ early) (NN stage) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) |ET| |BS|45:G07.700.320.249 69:G02.111.087.800 126:G02.111.087.800 262:A11.436.348 554:D02.654.442.200|ES| 19:1 102:1 195:1 383:1 412:1 529:1 900:1 1128:1 1129:1 1788:1 1909:1 2602:1 4289:1
-1 	|BT| (S (S (NP (NP (JJ Low) (JJ dietary) (NN folate) (NN intake)) (VP (VBN associated))) (VP (VBD increased) (NP (NN risk) (NN colon) (NN cancer))) (: ;)) (S (ADVP (RB however)) (, ,) (NP (JJ relevant) (JJ genetic) (NN animal) (NN model)) (VP (VBG lacking)))) |ET| |BS|19:B01.050 61:E05.318.740.600.800 224:D03.438.733.631.400 285:E05.598 595:G07.203.650.240 1109:E05.599.395.397|ES| 2:1 18:1 19:1 46:1 47:1 72:1 113:1 169:1 171:1 217:1 376:1 778:1 864:1 865:1 1387:1 2563:1 2594:1 3615:1
-1 	|BT| (S (S (NP (NNP Lycopene)) (VP (VBZ modulates) (SBAR (S (NP (NN initiation) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) (: :) (S (NP (NP (NN study) (JJ chromosomal) (NN abnormality)) (, ,) (NP (NN membrane) (NN fluidity) (JJ antioxidant) (NN defense) (NN system))))) |ET| |BS|554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260|ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1
-1 	|BT| (S (NP (JJ Male) (NN F344) (NN rat)) (VP (VBN treated) (S (NP (NP (CD one) (JJ powerful) (NNP Valerian) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN Valeriana) (NN sitchensis)) (-RRB- -RRB-))) (VP (VBZ dos) (NP (CD 0) (, ,) (CD 50) (, ,) (NP (NP (CD 500) (CD 5000) (NN ppm) (NN drinking) (NN water) (NN initiation) (NN hepatocarcinogenesis) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))) |ET| |BS|52:E02 554:D02.654.442.200 590:B01.050.050.199.520.760.200 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 1060:D01.045.250.875.300 1224:E05.318.740.872 1225:F01.658.780|ES| 2:1 10:1 14:1 19:1 368:1 637:1 849:1 900:1 1010:1 1099:1 1875:1 1952:1 2355:1 2653:1 3057:1 3185:1 3233:1 3635:1 3968:1 4163:1 4290:1 4291:1 4292:1 4293:1 4294:1 4295:1
-1 	|BT| (NP (NP (NP (JJ Male) (NN Malat1)) (: -) (: /) (: -)) (NP (S (NP (NN mouse) (JJ wild-type) (-LRB- -LRB-) (JJ WT) (-RRB- -RRB-) (NNS littermates)) (VP (VBD studied) (NP (NP (CD one) (NN year)) (NP (NP (NN treatment) (JJ genotoxic) (NN agent) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (, ,) (NP (JJ potent) (NN inducer) (NN liver) (NN cancer)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 775:E02.760.058|ES| 2:1 8:1 10:1 14:1 18:1 19:1 22:1 52:1 401:1 546:1 728:1 836:1 1010:1 1355:1 1452:1 1875:1 1952:1 1995:1 3329:1 3635:1 3791:1 4296:1
-1 	|BT| (NP (NP (NP (JJ Mechanistic) (NN Investigation) (NNP Toxaphene)) (NP (VBN Induced) (NN Mouse) (NN Liver) (NNS Tumors)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 225:E05.337 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 19:1 53:1 2127:1 2721:1 4297:1 4298:1 4299:1 4300:1
-1 	|BT| (S (NP (JJ Mechanistic) (NN study) (NN liver) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN flutamide) (NN rat)))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1172:D02.065.199.420 1226:E01.370.372.460|ES| 7:1 19:1 75:1 131:1 836:1 849:1 881:1 4057:1 4297:1
-1 	|BT| (S (NP (NNP Melatonin)) (VP (VBZ Activates) (NP (NP (JJ Endoplasmic) (NN Reticulum) (NN Stress) (NN Apoptosis) (NNS Rats)) (NP (JJ Diethylnitrosamine-Induced) (NN Hepatocarcinogenesis))))) |ET| |BS|39:G04.299.139.160 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 707:D03.438.473.914.481 1071:G04.434|ES| 19:1 1959:1 2738:1 3291:1 3664:1 4301:1 4302:1 4303:1 4304:1 4305:1
-1 	|BT| (S (NP (NN Melatonin)) (VP (VBZ prevents) (NP (NN deregulation) (NN sphingosine) (NN kinase/sphingosine) (NN 1-phosphate) (NN signaling) (NN pathway) (NN mouse) (NN model) (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 469:D08.811.913.696 554:D02.654.442.200 707:D03.438.473.914.481 1227:D01.029.260.700.675.374 1228:D02.705.400|ES| 19:1 52:1 72:1 195:1 303:1 304:1 383:1 402:1 2718:1 2732:1 2738:1 4306:1 4307:1 4308:1
-1 	|BT| (S (NP (NN Metformin)) (VP (VBZ inhibits) (NP (JJ early) (NN stage) (JJ diethylnitrosamineinduced) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450|ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (DT A) (JJ Solt-Farber) (JJ two-step) (NN test) (NN model) (NN hepatocarcino) (NN genesis)) (VP (VBD established) (S (NP (NP (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN AAF)) (-RRB- -RRB-))) (NN rat)) (VP (VBP investigate) (S (VP (VBG modifying) (NP (NP (NP (NN effect) (NN expression) (NN 6-glucosephosphatase)) (PRN (-LRB- -LRB-) (NP (NN G-6-Pase)) (-RRB- -RRB-))) (, ,) (NP (NN succinodehydrogenase) (-LRB- -LRB-) (NN SDH) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NN adenosine) (NN triphosphatase)) (PRN (-LRB- -LRB-) (NP (NN ATPase)) (-RRB- -RRB-))) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250|ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1
-1 	|BT| (FRAG (NP (NNS METHODS) (: :)) (NP (NN Liver) (NN fibrosis)) (VBD induced) (NP (NN mouse)) (VBG receiving) (NP (NP (NN bile) (NN duct) (NN ligation)) (PRN (-LRB- -LRB-) (NP (NN BDL)) (-RRB- -RRB-))) (NP (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NP (NN CCl) (PRN (-LRB- -LRB-) (CD 4) (-RRB- -RRB-) (-RRB- -RRB-)) (NN administration)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 168:E05.581 676:C06.552.630 1217:A02.513.514.100 1220:D02.455.526.439.150 1222:A03.159.183 1223:E04.426|ES| 10:1 14:1 19:1 52:1 104:1 319:1 412:1 548:1 565:1 949:1 1621:1 1622:1 2575:1 2721:1 4261:1 4278:1 4279:1 4282:1 4309:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (CD Twenty-four) (JJ Sprague-Dawley) (NN rat) (VBN treated) (NN diethylnitrosamine) (NN phenobarbital)) (VP (VBP induce) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 168:E05.581 554:D02.654.442.200 756:D03.383.742.698.253.650 769:B01.050.150.900.649.865.635.505.700.750|ES| 19:1 104:1 243:1 303:1 304:1 565:1 849:1 1099:1 1952:1 2685:1 2707:1 4310:1
-1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG developing) (NP (NP (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)) (VP (VBN subjected) (NP (JJ hydrodynamic) (NN gene) (NN delivery)))))) (VP (VBP overexpress) (NP (NN Gas1) (NN liver)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 242:A03.620 554:D02.654.442.200 1229:E04.520.252 1230:G01.342|ES| 9:1 19:1 303:1 304:1 583:1 590:1 836:1 2513:1 2732:1 3267:1 4311:1 4312:1 4313:1
-1 	|BT| (NP (NP (NNP Mode) (NN action) (NN analysis) (JJ synthetic) (NN pyrethroid) (JJ metofluthrin-induced) (NN rat) (NN liver) (NN tumor)) (: :) (NP (NN evidence) (JJ hepatic) (NN CYP2B) (NN induction) (NN hepatocyte) (NN proliferation))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 515:C04.588.274.623 1231:D02.455.849.575.812|ES| 7:1 19:1 38:1 104:1 299:1 661:1 736:1 836:1 838:1 849:1 1909:1 2013:1 3218:1 4314:1 4315:1 4316:1 4317:1
-1 	|BT| (NP (NP (NN Modulation) (NN energy) (JJ metabolic) (NN enzyme) (NN expression) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (JJ Chinese) (NN herb)) (, ,) (NP (NNP Huqi) (NNP San))) |ET| |BS|554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500|ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN mouse) (NN model) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis)) (, ,) (S (NP (NN rimonabant)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN formation)))) (, ,)) (VP (VBZ precedes) (NP (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 20:G03.495 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 824:C04.834.020|ES| 2:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 72:1 113:1 124:1 202:1 207:1 622:1 1431:1 1725:1 2533:1 2831:1 2913:1 2914:1 4318:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN mechanism) (NNS fibrates)) (VP (VBP induce) (NP (NN hepatocyte) (NN proliferation) (NN cholestasis)) (ADVP (RB still)) (VP (ADVP (RB fully)) (VBN understood)))) |ET| |BS|239:F02.463.188.357 262:A11.436.348 879:C06.130.120.135 1188:D02.241.081.114.968.500|ES| 2:1 19:1 162:1 243:1 299:1 622:1 776:1 889:1 979:1 1909:1 4130:1 4131:1
-1 	|BT| (S (NP (NN N-acetyl-L-cysteine)) (VP (VBD blocked) (SBAR (S (NP (NN EGFR) (NN activation)) (VP (VBD reduced) (NP (JJ N-nitrosodiethylamine-initiated) (NN hepatocarcinogenesis) (NN level) (NNP Cre-Ctrl) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259|ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1
-1 	|BT| (S (NP (JJ Nonalcoholic) (NN steatohepatitis)) (VP (VBD induced) (SBAR (S (NP (JJ high-fat) (NN diet)) (VP (VBZ promotes) (NP (JJ diethylnitrosamine-initiated) (JJ early) (NN hepatocarcinogenesis) (NN rat))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 509:C06.552.241.519 554:D02.654.442.200 694:G07.203.650.240.267|ES| 19:1 298:1 412:1 849:1 900:1 1128:1 1791:1 2191:1 2507:1 4092:1 4319:1
-1 	|BT| (S (NP (ADJP (RB Orally) (VBN administered)) (NN lycopene)) (VP (VBZ attenuates) (NP (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN rat)) (VP (VBG modulating) (NP (NP (NN Nrf-2)) (: /) (NP (NN HO-1) (NN Akt/mTOR) (NN pathway))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534|ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1
-1 	|BT| (NP (NP (PRP$ Our) (S (VP (VBP result) (S (VP (VBP provide) (NP (NP (ADJP (NN clue) (JJ molecular)) (NN event)) (VP (VBN involved) (NP (NN mechanism) (NN action) (JJ HCB-induced) (NN hepatocarcinogenesis)))))))))) |ET| |BS|742:G03.787 1232:D02.455.426.559.389.261.400|ES| 19:1 101:1 161:1 162:1 205:1 658:1 711:1 774:1 900:1 1142:1 2013:1 4320:1
-1 	|BT| (NP (PRP$ Our) (VP (VBP result) (NP (NP (NN show) (NNS HCCs)) (VP (VBG developing) (FRAG (X (SYM AOX)) (: -) (NP (NP (: /) (: -) (NN mouse) (NN share) (NN number)) (VP (VBN deregulated) (FRAG (-LRB- -LRB-) (NP (RP up) (: -) (VBN down-regulated) (-RRB- -RRB-) (NN gene) (JJ ciprofibrate-induced) (NN liver) (NN tumor)))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 142:I01.880.604 351:A17.360 515:C04.588.274.623|ES| 7:1 9:1 10:1 14:1 19:1 52:1 101:1 429:1 590:1 646:1 658:1 836:1 1132:1 1283:1 1965:1 4321:1 4322:1 4323:1 4324:1
-1 	|BT| (S (NP (JJ Overall) (NN finding)) (VP (VBP substantiate) (SBAR (S (NP (NN artesunate)) (VP (VBZ promotes) (SBAR (S (NP (JJ anti-tumour) (, ,) (JJ anti-proliferation) (NN apoptosis) (NN nitrosodiethylamine)) (VP (VBD mediated) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500|ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1
-1 	|BT| (S (NP (NP (NN Overdose) (NN acetaminophen)) (PRN (-LRB- -LRB-) (NP (NN APAP)) (-RRB- -RRB-))) (VP (VBP cause) (NP (NN liver) (NN injury) (JJ human) (NN animal)))) |ET| |BS|19:B01.050 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 242:A03.620 661:D02.065.199.092.040 1233:C25.775.383|ES| 10:1 14:1 19:1 36:1 46:1 836:1 1779:1 2412:1 2416:1 4193:1 4325:1
-1 	|BT| (NP (NP (NP (JJ Partial) (JJ hepatectomized) (NN rat)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (QP (CD 11) (CD 12))))) (-RRB- -RRB-))) (VP (VBN fed) (NP (NN diet) (VP (VBG containing) (S (CD 0) (, ,) (NP (CD 0.03) (, ,) (CD 0.06) (, ,) (CD 0.125) (ADJP (CD 0.25) (NN %)) (NN BNF)) (NP (NP (CD 6) (NN week) (JJ intraperitoneal) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP initiate) (NP (NN hepatocarcinogenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 595:G07.203.650.240 663:C16.320.565.398.500.330.500 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 286:1 369:1 580:1 581:1 783:1 785:1 849:1 900:1 1057:1 1120:1 1875:1 2191:1 2426:1 3230:1 3231:1 3529:1 3595:1 4037:1 4093:1 4163:1 4326:1 4327:1 4328:1 4329:1 4330:1
-1 	|BT| (S (NP (NP (NP (NNP Phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (JJ antiepileptic) (NN drug)) (VP (VBZ promotes) (NP (NP (NN hepatocarcinogenesis) (JJ rodent) (VBN administered) (JJ subsequent) (VBG initiating) (NN carcinogen)) (PP (IN like) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))))) |ET| |BS|279:D27.888.569.100 514:B01.050.150.900.649.865 554:D02.654.442.200 756:D03.383.742.698.253.650 1234:D27.505.954.427.080|ES| 10:1 14:1 19:1 191:1 298:1 900:1 1319:1 1875:1 1952:1 2019:1 2125:1 2173:1 2336:1 3496:1 4004:1 4331:1 4332:1
